venBio biotechnology firm tweaks top ranks as flagship soars 50.3% in 2014
By Simone Foxman
Thu Aug 7, 2014
Two years of outperformance push firm assets to $335 million.
Biotech-focused venBio Select Advisor is off to
another jaw-dropping year and has been formalizing its
infrastructure to accommodate rapid growth. The now-$335
million firm has hired a chief financial and compliance
officer, and it put a sole portfolio manager in charge of the
high-flying flagship hedge fund.
That hedge fund, the venBio Select Fund, generated a return
of 50.3% through July, according to a July 31 investor letter.
That compares with a rise of 4.50% for the Absolute Return
Global Equity Index. The fund’s assets have more
than tripled in that time period, from $44 million at yearend
2013, to $137 million as of July 31 (firmwide assets of $335
million also include a separate private equity fund). The hedge
fund began 2013 with less than $20 million and went on to
ISSN: 2151-1845 / CDC10004H
TAKE A FREE TRIAL
The full contents of this article are available to Absolute Return subscribers and trialists only.
To continue reading please, take a free trial, subscribe or log in.
Subscribers have unlimited access to all current and archive content. Start your subscription today - click on the button below.